1. Home
  2. SRE vs ARGX Comparison

SRE vs ARGX Comparison

Compare SRE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBA Sempra

SRE

DBA Sempra

N/A

Current Price

$76.60

Market Cap

56.3B

Sector

Utilities

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$928.86

Market Cap

55.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRE
ARGX
Founded
1998
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.3B
55.1B
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
SRE
ARGX
Price
$76.60
$928.86
Analyst Decision
Buy
Buy
Analyst Count
21
25
Target Price
$96.44
★ $1,150.61
AVG Volume (30 Days)
★ 3.7M
343.8K
Earning Date
11-05-2026
10-22-2026
Dividend Yield
★ 3.45%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.58
N/A
Revenue
★ $13,702,000,000.00
N/A
Revenue This Year
N/A
$53.06
Revenue Next Year
N/A
$23.03
P/E Ratio
$48.28
★ $33.69
Revenue Growth
★ 3.92
N/A
52 Week Low
$76.21
$661.85
52 Week High
$101.04
$1,072.75

Technical Indicators

Market Signals
Indicator
SRE
ARGX
Relative Strength Index (RSI) 31.67 51.26
Support Level $76.21 $836.30
Resistance Level $87.12 $941.15
Average True Range (ATR) 1.56 25.62
MACD -0.53 0.50
Stochastic Oscillator 2.03 50.08

Price Performance

Historical Comparison
SRE
ARGX

About SRE DBA Sempra

Sempra serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure Partners, 25% owned by Sempra, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: